Absence of EGFR C797S Mutation in Tyrosine Kinase Inhibitor-Naïve Non–Small Cell Lung Cancer Tissues

Standard

Absence of EGFR C797S Mutation in Tyrosine Kinase Inhibitor-Naïve Non–Small Cell Lung Cancer Tissues. / Oscorbin, Igor P.; Shadrina, Alexandra S.; Kozlov, Vadim V. и др.

в: Pathology and Oncology Research, Том 26, № 2, 01.04.2020, стр. 1229-1234.

Результаты исследований: Научные публикации в периодических изданиях › статья › Рецензирование

Harvard

Oscorbin, IP, Shadrina, AS, Kozlov, VV, Voitsitsky, VE & Filipenko, ML 2020, 'Absence of EGFR C797S Mutation in Tyrosine Kinase Inhibitor-Naïve Non–Small Cell Lung Cancer Tissues', Pathology and Oncology Research, Том. 26, № 2, стр. 1229-1234. https://doi.org/10.1007/s12253-019-00683-4

APA

Oscorbin, I. P., Shadrina, A. S., Kozlov, V. V., Voitsitsky, V. E., & Filipenko, M. L. (2020). Absence of EGFR C797S Mutation in Tyrosine Kinase Inhibitor-Naïve Non–Small Cell Lung Cancer Tissues. Pathology and Oncology Research, 26(2), 1229-1234. https://doi.org/10.1007/s12253-019-00683-4

Vancouver

Oscorbin IP, Shadrina AS, Kozlov VV, Voitsitsky VE, Filipenko ML. Absence of EGFR C797S Mutation in Tyrosine Kinase Inhibitor-Naïve Non–Small Cell Lung Cancer Tissues. Pathology and Oncology Research. 2020 апр. 1;26(2):1229-1234. doi: 10.1007/s12253-019-00683-4

Author

Oscorbin, Igor P. ; Shadrina, Alexandra S. ; Kozlov, Vadim V. и др. / Absence of EGFR C797S Mutation in Tyrosine Kinase Inhibitor-Naïve Non–Small Cell Lung Cancer Tissues. в: Pathology and Oncology Research. 2020 ; Том 26, № 2. стр. 1229-1234.

BibTeX

@article{8798c2b5843c4a929f05f9ae80ec2cb4,

title = "Absence of EGFR C797S Mutation in Tyrosine Kinase Inhibitor-Na{\"i}ve Non–Small Cell Lung Cancer Tissues",

abstract = "EGFR tyrosine-kinase inhibitors (TKIs) are used as targeted therapeutics for the treatment of advanced non–small cell lung cancer (NSCLC) with EGFR-activating mutations. EGFR C797S is common causes of acquired resistance to third-generation TKIs. There is wide-spread opinion that resistance-conferring mutation present even in a small proportion of cancer cells before the start of therapy could potentially predict poor response to a targeted drug. In our study, we tested whether C797S can be found in previously untreated NSCLCs. We analyzed DNA samples extracted from formalin-fixed paraffin-embedded (FFPE) tumor tissue sections of 470 lung adenocarcinoma patients, including 235 samples with activating EGFR mutations. Screening was performed using highly sensitive droplet digital PCR assay. No tumor samples with baseline C797S were identified. C797S does not occur in TKI-na{\"i}ve NSCLCs and provide evidence that screening for this mutation before TKIs administration may not be necessary.",

keywords = "C797S, Droplet digital PCR, EGFR, Non-small cell lung cancer, Osimertinib, OSIMERTINIB, MECHANISM, RESISTANCE, TUMORS",

author = "Oscorbin, {Igor P.} and Shadrina, {Alexandra S.} and Kozlov, {Vadim V.} and Voitsitsky, {Vladimir E.} and Filipenko, {Maxim L.}",

year = "2020",

month = apr,

day = "1",

doi = "10.1007/s12253-019-00683-4",

language = "English",

volume = "26",

pages = "1229--1234",

journal = "Pathology and Oncology Research",

issn = "1219-4956",

publisher = "Springer Netherlands",

number = "2",

}

RIS

TY - JOUR

T1 - Absence of EGFR C797S Mutation in Tyrosine Kinase Inhibitor-Naïve Non–Small Cell Lung Cancer Tissues

AU - Oscorbin, Igor P.

AU - Shadrina, Alexandra S.

AU - Kozlov, Vadim V.

AU - Voitsitsky, Vladimir E.

AU - Filipenko, Maxim L.

PY - 2020/4/1

Y1 - 2020/4/1

N2 - EGFR tyrosine-kinase inhibitors (TKIs) are used as targeted therapeutics for the treatment of advanced non–small cell lung cancer (NSCLC) with EGFR-activating mutations. EGFR C797S is common causes of acquired resistance to third-generation TKIs. There is wide-spread opinion that resistance-conferring mutation present even in a small proportion of cancer cells before the start of therapy could potentially predict poor response to a targeted drug. In our study, we tested whether C797S can be found in previously untreated NSCLCs. We analyzed DNA samples extracted from formalin-fixed paraffin-embedded (FFPE) tumor tissue sections of 470 lung adenocarcinoma patients, including 235 samples with activating EGFR mutations. Screening was performed using highly sensitive droplet digital PCR assay. No tumor samples with baseline C797S were identified. C797S does not occur in TKI-naïve NSCLCs and provide evidence that screening for this mutation before TKIs administration may not be necessary.

AB - EGFR tyrosine-kinase inhibitors (TKIs) are used as targeted therapeutics for the treatment of advanced non–small cell lung cancer (NSCLC) with EGFR-activating mutations. EGFR C797S is common causes of acquired resistance to third-generation TKIs. There is wide-spread opinion that resistance-conferring mutation present even in a small proportion of cancer cells before the start of therapy could potentially predict poor response to a targeted drug. In our study, we tested whether C797S can be found in previously untreated NSCLCs. We analyzed DNA samples extracted from formalin-fixed paraffin-embedded (FFPE) tumor tissue sections of 470 lung adenocarcinoma patients, including 235 samples with activating EGFR mutations. Screening was performed using highly sensitive droplet digital PCR assay. No tumor samples with baseline C797S were identified. C797S does not occur in TKI-naïve NSCLCs and provide evidence that screening for this mutation before TKIs administration may not be necessary.

KW - C797S

KW - Droplet digital PCR

KW - EGFR

KW - Non-small cell lung cancer

KW - Osimertinib

KW - OSIMERTINIB

KW - MECHANISM

KW - RESISTANCE

KW - TUMORS

UR - http://www.scopus.com/inward/record.url?scp=85068230271&partnerID=8YFLogxK

U2 - 10.1007/s12253-019-00683-4

DO - 10.1007/s12253-019-00683-4

M3 - Article

C2 - 31243697

AN - SCOPUS:85068230271

VL - 26

SP - 1229

EP - 1234

JO - Pathology and Oncology Research

JF - Pathology and Oncology Research

SN - 1219-4956

IS - 2

ER -

ID: 20709096